Heckyl Media Monitoring Tool showed a shift in average news sentiment (from negative to positive) for more than 20 companies from top 500 listed companies recently.
In our view, regular monitoring of media coverage can help corporate communications team to analyze news patterns and track movement in underlying sentiment for their company as well as competitors.
To remain relevant in today’s fast-changing world, a business organization needs to stay abreast with the latest happenings in the sector. It is extremely important for a company to keep an eye on its competitors to protect its business interest.
In our view, insights derived from media coverage can be useful for both Corporate Communications team and Senior Management. Read the rest of this entry »
Heckyl Sentiment index, which reflects a broad reading of collective sentiment for the Nifty companies, has turned mildly bearish for the 50-share index ending 2-month long bullish phase. Media sentiment for the broad-based index was in the bullish territory since the start of earnings season in April this year. The recent rate hike by the US Federal Reserve and selloff in technology shares weighed on the sentiment.
Voltas, the largest air conditioning company in India, has attracted positive press coverage recently. Heckyl News Analytics platform, which identifies positive and negative media coverage by scanning thousands of news and blog sources in real-time, has assigned the highest positive score of 100 to the Tata Group company for 3 out of 5 trading sessions during the previous week. Meanwhile, the average sentiment score for the past week stood at 84. Heckyl assigns sentiment score on a scale of -100 (very negative) to 100 (very positive).
Wockhardt was in action on Monday after the drug maker said the US health regulator agreed to abridged clinical trials for antibiotic being developed by the company. Wockhardt recorded a jump of 6.46 percent in share price on Monday.
The company is developing superdrug antibiotic WCK 5222. The drug is expected to be a life-saving therapy for serious hospital acquired infections. The aforesaid US FDA approval will help Wockhardt to speed up phase III clinical trials for the drug.